Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc. ( Monopar, the Company, we, us, and our and similar terms mean Monopar Therapeutics Inc. and its subsidiaries except where the context otherwise requires) is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investi…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$489M

EPS-$2.59

P/E-28.08

P/FCF–

EV/EBITDA-17.34

FCF Yield–

Div. Yield–

Net Debt/FCF–

Monopar Therapeutics Inc. intrinsic value

52-Week Range

$50.12$123.84

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue (FY)

$0.00

Net Income (TTM)

-$18M

▲ +12.0% YoY

Op. Margin

–

ROIC

-12.79%

▲ +28.4pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF

N/A

Op. Cash Flow (TTM)

-$12M

▼ -90.5% YoY

Net Debt

-$105M

Net Cash Position

Cash & Equiv.

$105M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with MNPR

CompareIntrinsic value

DERMJourney Medical Corp

$4.73+1.94%25

SPROSpero Therapeutics Inc.

$1.07+2.88%63

ABUSArbutus Biopharma Corporation

$4.06+4.64%60

LGVNLongeveron Inc.

$1.78+0.00%10

INOInovio Pharmaceuticals, Inc.

$1.62-2.41%10

SPRBSpruce Biosciences Inc.

$46.61+8.88%10

ALTAltimmune, Inc.

$2.12+3.92%10

AZTRAzitra Inc.

$0.82-7.69%19

Held by ETFs

MNPR is in 10 US ETFs. The largest of them, with MNPR's weight in each:

Monopar Therapeutics (MNPR) in three numbers

Quality score: 10/100; Best check: net debt, -$105M. Weakest: return on capital, -12.8%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -28.08; Negative: a loss over the last twelve months.; Financials

Questions about Monopar Therapeutics

Is Monopar Therapeutics a high-quality business?

Monopar Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$105M, and its weakest is return on capital at -12.8%. The Quality tab shows every check against its target.

Does Monopar Therapeutics (MNPR) pay a dividend?

No. Monopar Therapeutics (MNPR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 7.2% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in MNPR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MNPR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.